Emergent Biosolutions Inc (NYSE:EBS) EVP Adam Havey sold 7,972 shares of the business’s stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $60.00, for a total value of $478,320.00. Following the transaction, the executive vice president now owns 37,986 shares in the company, valued at approximately $2,279,160. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.
EBS stock traded up $2.75 on Wednesday, reaching $61.93. The company had a trading volume of 312,000 shares, compared to its average volume of 451,037. Emergent Biosolutions Inc has a 1 year low of $39.11 and a 1 year high of $71.19. The company has a debt-to-equity ratio of 0.73, a quick ratio of 2.14 and a current ratio of 3.17. The company’s fifty day moving average is $58.26 and its 200 day moving average is $55.83. The company has a market cap of $3.19 billion, a P/E ratio of 60.13 and a beta of 1.11.
Emergent Biosolutions (NYSE:EBS) last posted its earnings results on Thursday, February 20th. The biopharmaceutical company reported $1.57 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.67 by ($0.10). Emergent Biosolutions had a net margin of 4.94% and a return on equity of 14.19%. The company had revenue of $360.40 million during the quarter, compared to analysts’ expectations of $357.18 million. During the same period in the previous year, the company posted $0.75 EPS. Emergent Biosolutions’s quarterly revenue was up 33.3% compared to the same quarter last year. On average, sell-side analysts predict that Emergent Biosolutions Inc will post 3.43 earnings per share for the current year.
Several equities research analysts have recently commented on the company. Cowen assumed coverage on Emergent Biosolutions in a research note on Thursday, March 12th. They set a “hold” rating and a $67.00 price target on the stock. Wells Fargo & Co boosted their price target on Emergent Biosolutions from $66.00 to $75.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 25th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $70.83.
Emergent Biosolutions Company Profile
Emergent BioSolutions Inc, a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats (PHTs). Its products address PHTs, including chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travelers' diseases; and opioids.
Featured Story: Understanding Market Liquidity
Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.